Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers detected TMPRSS2-ERG fusions in 45% of analyzed prostate cancers, with those retaining interstitial genes showing lower risk of progression. The study suggests that identifying the formation mechanism of gene fusions could help stratify patients into more well-defined risk groups.
A recent study found that dietary isoflavone intake was associated with an elevated risk of advanced prostate cancer, but not non-advanced cases. Isoflavones are a type of phytoestrogen found in soybeans and other plants.
A study published in Annals of Oncology has identified genetic markers that may predict resistance to a specific therapy used for treating advanced prostate cancer. The researchers found that understanding the genetic markers of tumors can help healthcare providers match a therapy that is likely to succeed on the first try.
A new Northwestern Medicine study shows proton therapy outperforms intensity-modulated radiation therapy (IMRT) in five-year overall survival rates, with a 93.25% rate for proton patients compared to 88.43% for IMRT patients. Proton therapy also reduces complications and secondary malignancies, particularly for younger patients.
A recent study by UNC Lineberger Comprehensive Cancer Center researchers found that more than half of men with prostate cancer prefer preserving sexual function, but this preference was not strongly linked to the choice of treatment strategy. Active surveillance is widely recognized as the best option for preserving sexual function, ye...
A new gene expression biomarker has been developed to diagnose prostate cancer type and aggressiveness, enabling clinicians to tailor treatment plans. The study found the diagnostic test to be more effective than standard clinical tests in predicting aggressive disease.
Researchers found that nerves stimulate the formation of new blood vessels that promote tumor growth in prostate cancer. They discovered an "angio-metabolic switch" triggered by norepinephrine binding to endothelial cells, which changes how cells metabolize glucose, favoring glycolysis.
Researchers discovered a testosterone-related genetic variant that can predict individual patient responses to specific prostate cancer therapies. The studies suggest that men with this variant would benefit from personalized treatment plans targeting hormonal pathways.
Androgen receptor targeted imaging is emerging as a potential modality for early, rapid, and efficient diagnosis of prostate cancer. Current medical imaging reviews discuss traditional diagnostic approaches and summarize current imaging approaches using PSMA, BN, and AR targeted imaging.
A new study found that surgical cancer centers in England are investing heavily in unproven technologies to stay competitive, despite a lack of evidence on their effectiveness. This trend has led to the closure of several centers, with patients often traveling to alternative facilities offering robotic surgery.
The University of Texas at San Antonio has received a $354,617 grant to support the development of a novel microscope for detecting prostate cancer through urine samples. This noninvasive approach aims to improve accuracy compared to current clinical practices.
A groundbreaking collaboration has been awarded $2.5 million to explore an innovative new treatment path for breast and prostate cancer. The project aims to 'reprogram' hormone receptors, potentially transforming the lives of those affected by these cancers.
The STAMPEDE trial presents late-breaking results from two new treatments for patients with high risk prostate cancer. Patients starting long-term hormone therapy may benefit equally from docetaxel and abiraterone acetate plus prednisolone, with both treatments providing a survival advantage over standard care alone.
Researchers have developed a new approach to precisely identify and localize prostate cancer tumors while protecting healthy tissue. The double targeting ligand RPS-027 binds to both PSMA and albumin, reducing kidney uptake and increasing tumor-to-tissue ratios for improved therapeutic profile.
Guidelines recommending against routine PSA-based screening may be revised due to compatible evidence showing screening reduces prostate cancer mortality. The benefits of screening outweigh potential harms of overdiagnosis and overtreatment, but how to implement screening is still a question.
Researchers found that anti-hormone therapy can activate DNA repair enzyme PARP, causing cancer cells to become more aggressive. Combining PARP inhibitors with anti-hormone therapy treatment may help reduce prostate cancer recurrence and increase survival rates.
A new imaging technique has been developed to uncover oxygen levels in prostate tumours, potentially leading to a non-invasive way to determine which tumours are more difficult to treat. The technique uses light and sound to image the strength of blood vessels in tumours, helping doctors identify patients with harder-to-treat cancers.
Researchers at The Wistar Institute have developed a gene-based delivery system that instructs the body to generate therapeutic antibodies against cancer cells. This technology has shown promising results in treating prostate cancer by binding to cancer cells and recruiting immune cells, resulting in tumor shrinkage and improved survival.
Researchers at Mayo Clinic have identified a link between SPOP gene mutations and treatment resistance in prostate cancer. The discovery suggests ways to improve therapy by using these mutations as biomarkers. This breakthrough could lead to more effective treatments for this common and deadly form of cancer.
Researchers at Johns Hopkins Medicine discovered a biochemical process that gives prostate cancer cells the ability to change shape and invade other tissues. The study found that a gene called AIM1 is deleted in approximately 20-30% of prostate cancers confined to the gland and 40% of metastatic prostate cancers.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
Researchers mapped an acquired mutation altering DNA make-up in 50% of patient tumor samples, identifying a new target for therapy. The discovery highlights the power of mutations to influence epigenetics in cancer cells.
A systematic review and meta-analysis found that both bisphosphonates and denosumab improve bone mineral density in men with nonmetastatic prostate cancer receiving androgen deprivation therapy. Further trials are needed to confirm fracture reduction outcomes.
Men who are tall and obese have an increased risk of high grade prostate cancer and death from prostate cancer, according to a study published in BMC Medicine. The research found that height is not associated with overall prostate cancer risk but increases the risk of high grade disease and death by 21% and 17% respectively.
A 20-year study found that surgery for early-stage prostate cancer did not prolong life and often caused serious complications. Most men with early prostate cancer are more likely to survive with limited or no treatment.
Elena Castro, a Spanish researcher, is awarded the Prostate Cancer Foundation's Young Investigator Award for her project on DNA damage repair genes and their impact on advanced prostate cancer progression. The award supports her work to develop therapeutic strategies for patients with genetic defects.
Research found that genes responsible for differential RNA splicing contribute to tumor aggressiveness and drug resistance in African American men with prostate cancer. The study suggests these genetic variations lead to the production of protein isoforms that make tumors more aggressive, while also causing drug resistance.
A study published in Cell Chemical Biology highlights the need for new treatment approaches for treatment-resistant prostate cancer. Researchers found that effective steroidal anti-androgens share common metabolic activities, suggesting a potential strategy to improve efficacy.
A new three-in-one blood test developed by researchers at the Institute of Cancer Research can pick out men with advanced prostate cancer who are likely to benefit from treatment with PARP inhibitors. The test detects early signs of resistance and monitors cancer's evolution over time, allowing for timely adjustments to treatment.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.
Researchers at H. Lee Moffitt Cancer Center identify novel inhibitor (R)-9bMS that targets epigenetic modification of the androgen receptor gene, blocking growth in resistant prostate cancer cells. The discovery offers a new therapeutic option for castration-resistant prostate cancer patients who do not respond to enzalutamide.
Researchers demonstrated the efficacy of targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery, using a PSMA-targeting agent coupled with photosensitizers. The technique optimizes prostate cancer care by allowing visualization of tumors prior to surgery and providing real-time guidance to surgeons.
The EV-FPS test correctly identifies men with aggressive prostate cancer 40% more accurately than current PSA tests. It has the potential to eliminate up to 600-thousand unnecessary biopsies and reduce hospitalizations annually in North America.
Researchers at the University of Texas at Austin identified several plant-based compounds that can prevent or slow down prostate cancer growth. The study found that combining these compounds, such as ursolic acid and curcumin, with glutamine can block the nutrient uptake needed by prostate cancer cells.
A study found that black men are more concerned about the impact of treatment on their daily lives, recovery time, and cost, while white men prioritize quality of life and cancer cure. These differences in perceptions may contribute to racial disparities in prostate cancer treatment.
A clinical trial of nearly 2,000 men shows that adding abiraterone acetate to standard therapy for high-risk, advanced prostate cancer lowers the relative risk of death by 37% and increases the 3-year survival rate to 83%. The treatment also reduces the chance of relapse by 70% and serious bone complications by 50%.
Adding abiraterone acetate to standard hormonal therapy reduces the chance of death by 38% and doubles the median time until cancer worsens. Cancer growth is delayed by 18 months, but severe side effects like high blood pressure and liver enzyme abnormalities are more common with abiraterone.
The STAMPEDE trial found that adding abiraterone to standard hormone therapy improves prostate cancer survival in men with high-risk disease. The drug reduced disease progression by 70% and severe bone complications by more than half, leading to a 40% increase in overall survival.
Researchers are conducting a Phase 1 clinical trial using Lutetium 177Lu-PSMA-617 to target PSMA in men with progressive prostate cancer. The therapy aims to deliver precise radiation therapy and shrink the cancer, even in cases without visible tumors.
An educational session reduced pre-treatment distress in both prostate cancer patients and their partners, with sociodemographic and clinical characteristics having little impact on distress levels. The session was found to be equally effective for partners, emphasizing the need for targeted supportive care services for both individuals.
Researchers found that using MRI to detect lesions and guide biopsies increased standardized quality-adjusted life years for patients, and was cost-effective in 94.05% of simulations. This approach could change how doctors identify and sample cancer lesions, reducing unnecessary treatments and costs.
Researchers have developed a new blood test called IsoPSA that detects prostate cancer more accurately than current tests. The study found that IsoPSA can distinguish cancer from benign conditions and identify patients with high-risk disease, potentially reducing the need for unnecessary biopsies.
A Penn study has identified a new molecular chain of events that highlights novel targets to treat prostate cancer, which also shows promise in treating lung cancer. The research found that PKCε overexpression can cause cancer progression and that blocking CXCL13-CXCR5 molecules may be a new cancer treatment.
A new study found that treating prostate cancer with a single high dose of precise radiation results in fewer hospital trips, lower toxicity, and improved quality of life compared to traditional treatments. Patients reported high satisfaction with the convenient outpatient procedure.
Researchers discovered that tumor cells in patients with advanced prostate cancer are reprogrammed, reducing response to anti-androgen therapy and creating more aggressive tumors. SOX11 acts as a key regulator in this process, which may be targeted for new treatments.
A new blood test can detect multiple copies of the androgen receptor gene in men with advanced prostate cancer, indicating a lower likelihood of responding to targeted treatments. The test could help doctors personalize treatment options for patients.
Researchers at Duke University discovered that CYP17A1 inhibitors function as competitive AR antagonists, indicating a more effective role in treating prostate cancer. The study found that these inhibitors can inhibit the growth of prostate tumor cells expressing treatment-resistant AR mutations.
A study of 7,000 Italian men found that drinking more than three cups of Italian-style coffee per day reduces prostate cancer risk by over 50%. Laboratory tests confirmed the protective effect of caffeine in reducing cancer cell proliferation and metastasis.
A new biopsy technique combining MRI and ultrasound improves prostate cancer detection. Researchers found that patients are willing to pay $1,598 more for a biopsy increasing the likelihood of detecting all types of prostate cancer from 43% to 51%.
Black men in the US are at a higher risk of developing preclinical prostate cancer and having it progress quickly to advanced stages. Screening policies may need to be tailored to their higher-risk status.
A new study by the American Cancer Society found that prostate specific antigen (PSA) testing rates among men 50 years or older have leveled off at 32.1%. This trend is notable given previous declines in PSA screening rates, which dropped from 37.8% in 2010 to 30.8% in 2013.
The study found that sexual function declined after all treatments, with robotic surgery patients regaining function closest to brachytherapy and radiation levels. Urinary incontinence also decreased most for surgical patients, with robotic surgery showing slight improvement over open surgery.
Researchers demonstrate that an aggressive combination of systemic therapy and local therapy can eliminate all detectable disease in selected patients with metastatic prostate cancer. One-fifth of the patients treated had no detectable disease, with undetectable PSA and normal testosterone levels after 20 months.
A recent review suggests that a family history of prostate cancer does not increase the risk of more aggressive cancer progression. Men with a family history should discuss risks and options with their doctor, and further research is needed to confirm these findings, particularly among African American men.
A clinical trial found that twice-weekly yoga led to better physical, sexual, emotional, and social health in men with prostate cancer. Patients who practiced yoga reported lower fatigue and improved urinary function compared to those without yoga.
Researchers at the University of Missouri have discovered a new biomarker, TSPYL5, that can help identify prostate cancer progression and predict treatment response. The testis-specific protein varied between normal patients and tumor tissues with different Gleason scores, allowing clinicians to make rational decisions in treating the ...
Researchers have identified a set of molecules in urine that are present in 90% of prostate cancer patients but not in healthy individuals. This discovery could lead to the development of a non-invasive test for early detection of prostate cancer, potentially reducing unnecessary biopsies and improving patient outcomes.
The study found that E4 lowered testosterone levels in healthy male volunteers, with decreasing total and free testosterone, FSH, and estradiol levels. The hormone was well-tolerated, with only libido decrease and nipple tenderness reported.
Researchers have developed selective androgen receptor degraders (SARDs) that can degrade all forms of the androgen receptor, potentially providing advanced treatment options for men with castration-resistant prostate cancer. These molecules inhibit the growth of aggressive prostate cancers that are unresponsive to other treatments.